Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Therapeutics × Other × Clear all

Phase

Status

Sponsor Class

OTHER 3 OTHER_GOV 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6 Genitourinary 6 CNS 4 Breast 4 Tumor-Agnostic 3 Other solid neoplasm 3 Head & Neck 3 Dermatologic 3 Gynecologic 2 Plasma cell 1 Other hematologic neoplasm 1 Other 1 Myeloid 1 Lymphoid 1 Gastrointestinal 1

Conditions

Mucositis 1 Head and Neck Neoplasms 1

Interventions

naloxegol 5 alvimopan 5 tegaserod 3 Radiotherapy 3 Injections 3 angiotensin I (1-7) 2 RRx-001 2 Cisplatin 2 tempol 1 prucalopride 1 oxycodone naloxone combination 1 naldemedine 1 methylnaltrexone 1 linaclotide 1 licogliflozin 1 hydrated silica gel-based toothpaste 1 brilacidin 1 apraglutide 1 aluminum hydroxide, magnesium hydroxide, drug combination 1 Xylitol 1 Water 1 Therapeutics 1 Testosterone Propionate 1 Robotic Surgical Procedures 1 Radiotherapy, Intensity-Modulated 1 Phenylephrine 1 Oxycodone 1 Naloxone 1 Lubiprostone 1 Lidocaine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04046250 2023-08-25

TK112690

Tosk, Inc.

Phase 2 Completed

22 enrolled 10 charts

Head & NeckOther

Head and Neck Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡